Carisma Therapeutics (NASDAQ:CARM) Upgraded at EF Hutton Acquisition Co. I

EF Hutton Acquisition Co. I upgraded shares of Carisma Therapeutics (NASDAQ:CARM) to a strong-buy rating in a report released on Wednesday, Zacks.com reports.

Carisma Therapeutics Price Performance

NASDAQ CARM opened at $1.00 on Wednesday. Carisma Therapeutics has a twelve month low of $0.80 and a twelve month high of $3.42. The company has a debt-to-equity ratio of 1.39, a quick ratio of 3.25 and a current ratio of 3.25. The stock has a market capitalization of $41.54 million, a PE ratio of -0.56 and a beta of 1.49. The stock has a 50-day simple moving average of $1.00 and a 200 day simple moving average of $1.18.

Carisma Therapeutics (NASDAQ:CARM) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.09. Carisma Therapeutics had a negative return on equity of 344.89% and a negative net margin of 350.08%. The business had revenue of $9.20 million during the quarter, compared to analysts’ expectations of $3.65 million. Research analysts anticipate that Carisma Therapeutics will post -1.43 EPS for the current year.

Hedge Funds Weigh In On Carisma Therapeutics

An institutional investor recently raised its position in Carisma Therapeutics stock. Vanguard Group Inc. lifted its stake in Carisma Therapeutics, Inc. (NASDAQ:CARM) by 0.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,579,961 shares of the company’s stock after buying an additional 11,200 shares during the period. Vanguard Group Inc. owned about 3.80% of Carisma Therapeutics worth $3,587,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 44.27% of the company’s stock.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.